Dicerna Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Dicerna Pharmaceuticals Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 24 Dec 2020 | Lorem |
Dicerna to welcome CRO pitches for Phase I DCR-undisclosed liver trial in mid-2020, decisions by late 2020, CEO says | 21 Nov 2019 | Shuan Sim |
Alnylam’s early lumasiran data provides optimism for Phase III primary hyperoxaluria type 1 surrogate endpoint, but clinical outcomes beyond Phase III key for long-term use, experts say | 28 Jun 2019 | Manasi Vaidya |
Dicerna appoints Premier Research as CRO for Phase II primary hyperoxaluria study of DCR-PHXC, expects open-label extension data by YE, says CEO | 06 May 2019 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward